Pharmaceutical

Risk adjusted net present value: What is the current valuation of Enliven Therapeutics’s ELVN-002?

ELVN-002 is a small molecule commercialized by Enliven Therapeutics, with a leading Phase I program in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Apr 17, 2024 - 00:00
ELVN-002 is a small molecule commercialized by Enliven Therapeutics, with a leading Phase I program in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s...

Next Article

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rankings

Oct 17, 2023

STAT+: Solicitor general urges Supreme Court to review ‘skinny labeling’ and generic drug access

STAT+: Solicitor general urges Supreme Court to review ...

Mar 30, 2023

STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace

STAT+: Patent thickets and terminal disclaimers: How ph...

Dec 21, 2023